 WILMETTE, Ill., Feb. 09, 2021 GLOBE NEWSWIRE -- Monopar Therapeutics Inc. Nasdaq: MNPR, a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan. 